9. Revolution Medicines Inc. (NASDAQ:RVMD)
Recent reporting linked share-price weakness to questions surrounding FDA review documents and KRAS subgroup data. The article angle is what those documents actually establish and how their findings could affect the commercial outlook.
READ THIS: Revolution Medicines (RVMD) Has an Approved Cancer Drug but Can Sales Follow?
